Literature DB >> 32249490

Systematic characterization of non-coding RNAs in triple-negative breast cancer.

Jie Mei1, Leiyu Hao2, Huiyu Wang1, Rui Xu2, Yan Liu2, Yichao Zhu2,3, Chaoying Liu1.   

Abstract

Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer with negativity for oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2). Non-coding RNAs (ncRNAs) make up most of the transcriptome and are widely present in eukaryotic cells. In recent years, emerging evidence suggests that ncRNAs, mainly microRNAs (miRNAs), long ncRNAs (lncRNAs) and circular RNAs (circRNAs), play prominent roles in the tumorigenesis and development of TNBC, but the functions of most ncRNAs have not been fully described. In this review, we systematically elucidate the general characteristics and biogenesis of miRNAs, lncRNAs and circRNAs, discuss the emerging functions of these ncRNAs in TNBC and present future perspectives in clinical practice.
© 2020 The Authors. Cell Proliferation Published by John Wiley & Sons Ltd.

Entities:  

Year:  2020        PMID: 32249490     DOI: 10.1111/cpr.12801

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  18 in total

1.  Small non-coding RNA profiling in breast cancer: plasma U6 snRNA, miR-451a and miR-548b-5p as novel diagnostic and prognostic biomarkers.

Authors:  Luděk Záveský; Eva Jandáková; Vít Weinberger; Luboš Minář; Veronika Hanzíková; Daniela Dušková; Adéla Faridová; Radovan Turyna; Ondřej Slanař; Aleš Hořínek; Milada Kohoutová
Journal:  Mol Biol Rep       Date:  2022-01-07       Impact factor: 2.316

2.  SOX2-OT induced by PAI-1 promotes triple-negative breast cancer cells metastasis by sponging miR-942-5p and activating PI3K/Akt signaling.

Authors:  Wenwen Zhang; Shuofei Yang; Datian Chen; Daolu Yuwen; Juan Zhang; Xiaowei Wei; Xin Han; Xiaoxiang Guan
Journal:  Cell Mol Life Sci       Date:  2022-01-07       Impact factor: 9.261

Review 3.  Triple-negative breast cancer: A run-through of features, classification and current therapies.

Authors:  Meghana Manjunath; Bibha Choudhary
Journal:  Oncol Lett       Date:  2021-05-05       Impact factor: 2.967

4.  Long non-coding RNA CASC9/microRNA-590-3p axis participates in lutein-mediated suppression of breast cancer cell proliferation.

Authors:  Yuxia Zhang; Jingzhi Chang; Weiwei Jiang; Xin Ye; Shanfeng Zhang
Journal:  Oncol Lett       Date:  2021-05-20       Impact factor: 2.967

5.  Polycomb repressor complex 2 function in breast cancer (Review).

Authors:  Courtney J Martin; Roger A Moorehead
Journal:  Int J Oncol       Date:  2020-09-17       Impact factor: 5.650

Review 6.  Molecular Pathogenesis of Intrahepatic Cholestasis of Pregnancy.

Authors:  Jianping Xiao; Zeying Li; Yutong Song; Yujie Sun; Hanfei Shi; Daozhen Chen; Yan Zhang
Journal:  Can J Gastroenterol Hepatol       Date:  2021-05-30

7.  Prognostic Biomarkers on a Competitive Endogenous RNA Network Reveals Overall Survival in Triple-Negative Breast Cancer.

Authors:  Wenxing Qin; Feng Qi; Jia Li; Ping Li; Yuan-Sheng Zang
Journal:  Front Oncol       Date:  2021-06-11       Impact factor: 6.244

8.  Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab.

Authors:  Jie Li; Maoguang Ma; Xuesong Yang; Maolei Zhang; Jingyan Luo; Huangkai Zhou; Nunu Huang; Feizhe Xiao; Bingquan Lai; Weiming Lv; Nu Zhang
Journal:  Mol Cancer       Date:  2020-09-11       Impact factor: 27.401

9.  Development of a novel immune-related lncRNA signature as a prognostic classifier for endometrial carcinoma.

Authors:  Jinhui Liu; Jie Mei; Yichun Wang; Xucheng Chen; Jiadong Pan; Laigen Tong; Yan Zhang
Journal:  Int J Biol Sci       Date:  2021-01-01       Impact factor: 6.580

10.  The lncRNA ADAMTS9-AS2 Regulates RPL22 to Modulate TNBC Progression via Controlling the TGF-β Signaling Pathway.

Authors:  Kan Ni; Zhiqi Huang; Yichun Zhu; Dandan Xue; Qin Jin; Chunhui Zhang; Changjiang Gu
Journal:  Front Oncol       Date:  2021-06-09       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.